Showing presentation: reset
The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers
James G Christensen
Mirati Therapeutics, San Diego, CA, United States